Bemarituzumab in Patients With FGFR2b-Selected Gastric or Gastro-Oesophageal Junction Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
Lancet Oncol 2022 Oct 13;[EPub Ahead of Print], ZA Wainberg, PC Enzinger, YK Kang, S Qin, K Yamaguchi, IH Kim, A Saeed, SC Oh, J Li, HM Turk, A Teixeira, C Borg, E Hitre, AA Udrea, GG Cardellino, RG Sanchez, H Collins, S Mitra, Y Yang, DVT Catenacci, KW LeeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.